POSTDOCTORAL SCIENTIST – Immunology Group
? Salary in the range of £28,500 – £38,000 dependent upon qualifications and experience
• Job Ref: PI/12/26
• 3 year fixed term contract
The Paterson Institute for Cancer Research is a leading cancer centre of excellence which is an Institute of The University of Manchester. The Institute is core funded by Cancer Research UK, the largest independent cancer research organisation in the world.
Our aim is to gain a greater understanding of the fundamental basis of how cancer develops and apply that knowledge to develop new diagnostic tests, potential treatments and better ways to predict the outcomes.
Our advanced research spans the whole spectrum of cancer research, from programmes investigating molecular and cellular basis of cancer, to those focussed on translational research and development of therapeutics. The Institute has outstanding laboratory facilities and exceptional core services, including microarrays, confocal microscopy, bioinformatics, histology, and access to mass-spectrometry based proteomics.
The Institute is situated in Manchester, England, a vibrant and dynamic city, half an hour from Manchester International Airport, and surrounded by some of the most beautiful countryside in the UK.
A three year position is available in the laboratory of Peter L Stern to investigate the role of 5T4 in cancer and development using in vitro and in vivo molecular biological approaches.
The successful applicant should have a PhD in a relevant biomedical topic and preferably a strong relevant background in molecular biology and biochemistry is desirable.
Our research theme is the investigation of shared properties of developmental tissues and cancer cells with a view to identifying new targets for diagnosis, prognosis or therapy. 5T4 oncofoetal glycoprotein expression has been shown to influence adhesion, cytoskeletal organization and motility, properties which might account for its association with poorer clinical outcome in many cancers. We have recently shown that 5T4 functionally regulates CXCL12 and canonical Wnt/Β catenin/non-canonical pathway signalling (1-3). The research programme is investigating 5T4 modulation of chemokine and Wnt signalling in tumour spread and survival, 5T4 transcriptional regulation and therapeutic agents which induce or utilize 5T4 specific antibody to target cancer cells.
The successful applicant should preferably have a strong relevant background in molecular biology including transcriptional regulation and biochemistry.
1. Southgate, TD, McGinn OJ, Castro FV, Rutkowski AJ, , Al-Muftah M, Marinov G, Smethurst GJ, Shaw D, Ward CM, Miller CJ, and Stern PL. (2010). CXCR4 Mediated Chemotaxis is Regulated by 5T4 Oncofetal Glycoprotein in Mouse Embryonic Cells. PLoS ONE 5(4): e9982. doi:10.1371/journal.pone.0009982.
2. Castro FV, McGinn OJ, Krishnan S, Marinov G, Li J, Rutkowski AJ, Elkord E, Burt D, Holland M, Vaghjiani R, Gallego A, Saha V and Stern, PL. 5T4 oncofoetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype, Leukemia accepted article preview 23 January 2012; doi:10.1038/leu.2012.18. 3. Kagermeier-Schenk B, Wehner D, Özhan-Kizil G, Yamamoto H, Li J, Kirchner K, Hoffmann C, Stern PL, Kikuchi A, Schambony A and Weidinger G (2011). The transmembrane protein Waif1/5T4 inhibits Wnt/b-catenin signaling and activates noncanonical Wnt pathways by modifying LRP6 subcellular localization. Developmental Cell doi:10.1016/j.devcel.2011.10.015
Informal enquires should be directed to Peter L Stern, eval(unescape('%64%6f%63%75%6d%65%6e%74%2e%77%72%69%74%65%28%27%3c%61%20%68%72%65%66%3d%22%6d%61%69%6c%74%6f%3a%70%73%74%65%72%6e%40%70%69%63%72%2e%6d%61%6e%2e%61%63%2e%75%6b%22%3e%70%73%74%65%72%6e%40%70%69%63%72%2e%6d%61%6e%2e%61%63%2e%75%6b%3c%2f%61%3e%27%29%3b')) or Tel: 0161 446 3127
Deadline: Contact employer